Investor Relations

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Stock Market
NASDAQSNGX
Latest News
Oct 3, 2024

U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing PRINCETON, N.J., Oct. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...

Sep 16, 2024

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

Sep 3, 2024

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a...

All Press Releases

IR Contacts

29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Telephone: 609-538-8200
ir@soligenix.com

Subscribe For Alerts

If you would like to receive our Investor Relations updates, please sign up for email alerts. 

 

 

Sign Up